四環醫藥(00460.HK)收購新一代氨基糖苷類抗生素Plazomicin中國所有權益及知識產權
格隆匯2月20日丨四環醫藥(00460.HK)發佈公告，集團附屬全資子公司軒竹(香港)醫藥科技有限公司(“軒竹”)，已收購於美國特拉華州註冊成立的公司Achaogen,Inc.(“Achaogen”)於大中華區(包括中國大陸及港澳台)有關新一代氨基糖苷類抗生素plazomicin的所有權益及知識產權。
根據披露，Plazomicin是由Achaogen開發的新一代半合成氨基糖苷類抗生素，主要通過與細菌核糖體30S亞基結合，產生抑菌作用，開發用於治療多藥耐藥(“MDR”)革蘭氏陰性菌腸桿菌科細菌導致的嚴重感染，包括對碳青黴烯類抗生素耐藥的腸桿菌。在中國，MDR菌感染途徑主要為醫院獲得性感染，受感染者多為各種原因導致的免疫力低下者。如新型冠狀病毒等病毒感染後，會侵犯淋巴細胞破壞人體的免疫系統，當人體的免疫力降低時便有可能出現繼發細菌感染，增加醫院獲得性進一步感染機會。
臨牀治療中針對MDR菌可選藥物非常有限，但僅有的幾種治療選擇卻因腎毒性嚴重等問題而使臨牀應用受到限制。Plazomicin注射劑於2018年6月經美國食品藥品管理局(FDA)批准上市，用於治療成人複雜性尿道感染及急性腎盂腎炎。目前，臨牀應用證實，plazomicin的腎毒性風險明顯低於前幾代氨基糖苷類藥物。
隨着細菌對現有抗菌藥物不斷耐藥，超級細菌已成為人類面臨的最嚴重的健康威脅。世界衞生組織(WHO)預測到2050年每年將有1,000萬人死於超級細菌感染。醫藥市場調研機構EvaluatePharma預測，plazomicin的年銷售額在2022年將達到3.13億美元。而在大中華區上市後，集團預期plazomicin將帶來可觀的經濟收益。
此外，集團自主研發的一類創新藥碳青黴烯類廣譜抗生素“百納培南”，其針對複雜性尿道感染的II期臨牀試驗已在中國多家臨牀試驗單位開展，且進展順利，預期今年下半年進入III期臨牀試驗。
公告表示，集團另一抗感染產品“阿奇黴素膠囊”擬中選第二批全國藥品集中採購。該藥品的規格為0.25克*6粒╱盒，擬中選價為人民幣5.46元╱盒。該藥品遴選的供應省份為江蘇、山東、福建、遼寧、黑龍江、甘肅、廣西及西藏8省，將提供最低3,000萬粒的藥品。阿奇黴素膠囊在本次集採中中選，將有利於集團阿奇黴素膠囊迅速打開中國國內銷售市場，提高市場佔有率，並將進一步促進集團在抗感染藥物領域的快速發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
